128 related articles for article (PubMed ID: 35833215)
1. Cost-effectiveness of biweekly cetuximab plus chemotherapy in first-line treatment for RAS wild-type metastatic colorectal cancer.
Giuliani J
J Oncol Pharm Pract; 2022 Oct; 28(7):1674-1676. PubMed ID: 35833215
[No Abstract] [Full Text] [Related]
2. Cost-Effectiveness Analysis of First-Line FOLFIRI Combined With Cetuximab or Bevacizumab in Patients With RAS Wild-Type Left-Sided Metastatic Colorectal Cancer.
Han J; Xiao D; Tan C; Zeng X; Hu H; Zeng S; Jiang Q; She L; Yao L; Li L; Tang L; Ma J; Huang J; Shen L
Cancer Control; 2020; 27(1):1073274820902271. PubMed ID: 32107929
[TBL] [Abstract][Full Text] [Related]
3. Cetuximab Maintenance Therapy in Patients with Unresectable Wild-Type RAS and BRAF Metastatic Colorectal Cancer: A Single-Institute Prospective Study.
Jiang T; Chen H; Zheng J; Du B; Yang B; Liu Q; Zhong D; Wang X; Wang H; Lin M; Lai J; Hou P; Lin X
Adv Ther; 2020 Jun; 37(6):2829-2840. PubMed ID: 32378072
[TBL] [Abstract][Full Text] [Related]
4. Model-Based Cost-Effectiveness Analysis of Panitumumab Plus FOLFIRI for the Second-Line Treatment of Patients with Wild-Type Ras Metastatic Colorectal Cancer.
Shi Y; Wan X; Tan C; Li J; Peng L
Adv Ther; 2020 Feb; 37(2):847-859. PubMed ID: 31902066
[TBL] [Abstract][Full Text] [Related]
5. Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome.
García-Foncillas J; Díaz-Rubio E
Clin Transl Oncol; 2010 Aug; 12(8):533-42. PubMed ID: 20709651
[TBL] [Abstract][Full Text] [Related]
6. Economic Analysis of First-Line Treatment with Cetuximab or Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer in England.
Tikhonova IA; Huxley N; Snowsill T; Crathorne L; Varley-Campbell J; Napier M; Hoyle M
Pharmacoeconomics; 2018 Jul; 36(7):837-851. PubMed ID: 29498000
[TBL] [Abstract][Full Text] [Related]
7. FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial.
Heinemann V; von Weikersthal LF; Decker T; Kiani A; Kaiser F; Al-Batran SE; Heintges T; Lerchenmüller C; Kahl C; Seipelt G; Kullmann F; Moehler M; Scheithauer W; Held S; Miller-Phillips L; Modest DP; Jung A; Kirchner T; Stintzing S
Br J Cancer; 2021 Feb; 124(3):587-594. PubMed ID: 33154570
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of FOLFIRI + cetuximab vs FOLFIRI + bevacizumab in the first-line treatment of
Stintzing S; van Oostrum I; Pescott CP; Ronga P; Heeg B; Heinemann V
J Med Econ; 2020 May; 23(5):448-455. PubMed ID: 31903807
[No Abstract] [Full Text] [Related]
9. Cost-effectiveness analysis of cetuximab combined with chemotherapy as a first-line treatment for patients with RAS wild-type metastatic colorectal cancer based on the TAILOR trial.
Wang H; Huang L; Gao P; Zhu Z; Ye W; Ding H; Fang L
BMJ Open; 2020 Feb; 10(2):e030738. PubMed ID: 32051297
[TBL] [Abstract][Full Text] [Related]
10. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status.
Van Cutsem E; Köhne CH; Láng I; Folprecht G; Nowacki MP; Cascinu S; Shchepotin I; Maurel J; Cunningham D; Tejpar S; Schlichting M; Zubel A; Celik I; Rougier P; Ciardiello F
J Clin Oncol; 2011 May; 29(15):2011-9. PubMed ID: 21502544
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapy of metastatic colorectal cancer.
Prescrire Int; 2010 Oct; 19(109):219-24. PubMed ID: 21180382
[TBL] [Abstract][Full Text] [Related]
12. Cetuximab as First-line Treatment for Metastatic Colorectal Cancer: Caution With Interpretation of Cost-Effectiveness Results Toward Medical Decision Making.
Franken MD; Koopman M; van Oijen MG
Am J Clin Oncol; 2016 Apr; 39(2):214. PubMed ID: 26999056
[No Abstract] [Full Text] [Related]
13. Cetuximab as first-line treatment for metastatic colorectal cancer (mCRC): a model-based economic evaluation in Indonesia setting.
Putri S; Saldi SRF; Khoe LC; Setiawan E; Megraini A; Santatiwongchai B; Nugraha RR; Permanasari VY; Nadjib M; Sastroasmoro S; Armansyah A
BMC Cancer; 2023 Aug; 23(1):731. PubMed ID: 37553566
[TBL] [Abstract][Full Text] [Related]
14. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Van Cutsem E; Köhne CH; Hitre E; Zaluski J; Chang Chien CR; Makhson A; D'Haens G; Pintér T; Lim R; Bodoky G; Roh JK; Folprecht G; Ruff P; Stroh C; Tejpar S; Schlichting M; Nippgen J; Rougier P
N Engl J Med; 2009 Apr; 360(14):1408-17. PubMed ID: 19339720
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting.
Asseburg C; Frank M; Köhne CH; Hartmann JT; Griebsch I; Mohr A; Osowski U; Schulten J; Mittendorf T
Clin Ther; 2011 Apr; 33(4):482-97. PubMed ID: 21635994
[TBL] [Abstract][Full Text] [Related]
16. Multicenter Phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer: The FLEET study.
Soda H; Maeda H; Hasegawa J; Takahashi T; Hazama S; Fukunaga M; Kono E; Kotaka M; Sakamoto J; Nagata N; Oba K; Mishima H
BMC Cancer; 2015 Oct; 15():695. PubMed ID: 26467662
[TBL] [Abstract][Full Text] [Related]
17. A Cost-effectiveness Analysis of Adding Cetuximab to the First-line Treatment of Metastatic Colorectal Carcinoma in Iran; Considering Genetic Screening for Precision Medicine.
Yousefi N; Salimi A; Mohammadnezhad G; Taheri S; Peiravian F
J Gastrointest Cancer; 2023 Dec; 54(4):1212-1219. PubMed ID: 36622516
[TBL] [Abstract][Full Text] [Related]
18. The effectiveness of cetuximab and panitumumab when combined with FOLFIRI in second-line treatment of KRAS wild type metastatic colorectal cancers. Single centre experience.
Gürsoy P; Çakar B; Almuradova E; Karateke M; Doğanavşargil B; Sezak M; Harman M; Karabulut B
J Chemother; 2021 May; 33(3):180-186. PubMed ID: 33349195
[TBL] [Abstract][Full Text] [Related]
19. FOLFIRI and Cetuximab Every Second Week for First-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer According to Phosphatase and Tensin Homolog Expression: A Phase II Study.
Personeni N; Rimassa L; Verusio C; Barni S; Rubino L; Bozzarelli S; Villa E; Carnaghi C; Tronconi MC; Gerardi C; Galli F; Floriani I; Destro A; Raschioni C; Labianca R; Santoro A
Clin Colorectal Cancer; 2015 Sep; 14(3):162-9. PubMed ID: 25861836
[TBL] [Abstract][Full Text] [Related]
20. Randomized study of weekly irinotecan plus high-dose 5-fluorouracil (FUIRI) versus biweekly irinotecan plus 5-fluorouracil/leucovorin (FOLFIRI) as first-line chemotherapy for patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors Study.
Aranda E; Valladares M; Martinez-Villacampa M; Benavides M; Gomez A; Massutti B; Marcuello E; Constenla M; Cámara JC; Carrato A; Dueñas R; Reboredo M; Navarro M; Díaz-Rubio E
Ann Oncol; 2009 Feb; 20(2):251-7. PubMed ID: 18718892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
